Evaxion Biotech AS (EVAX NASDAQ) stock market data APIs
$3.5982
0.14(3.9%)
as of March 26, 2026
Try our APIs with
free plan!
Evaxion Biotech AS Financial Data Overview
Price chart is built with
Anychart
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Prev. Close
3.5982
Open
3.7391
High
3.7558
Low
3.5453
52 wk Range
1.2-12.15
Market Cap
29 941 K
Shares Outstanding
8 340 K
Revenue
7 528 K
EPS
-0.01
Beta
0.321
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evaxion Biotech AS data using free add-ons & libraries
Get Evaxion Biotech AS Fundamental Data
Evaxion Biotech AS Fundamental data includes:
- Net Revenue: 7 528 K
- EBITDA: -8 873 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: -0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evaxion Biotech AS News
New
Notice to convene Evaxion’s Annual General Meeting
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces th...
Evaxion to present new data at AACR Annual Meeting
Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion’s AI-Immunology�...
Evaxion Biotech ADS GAAP EPS of -$0.02 beats by $0.01
* Evaxion Biotech ADS press release [https://seekingalpha.com/pr/20425951-evaxion-announces-business-update-and-full-year-2025-financial-results] (EVAX [https://seekingalpha.com/symbol/EVAX]): FY GAA...
Evaxion announces business update and full year 2025 financial results
Evaxion COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, prov...
Get Evaxion Biotech AS fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
